Effect of Oral Atorvastatin on CD4+CD25+ Regulatory T Cells, FoxP3 Expression, and Prognosis in Patients With ST-Segment Elevated Myocardial Infarction Before
2011-10-101136
Objective: Our objective was to explore the effects of atorvastatinon changes of CD4+CD25+ regulatory T cells (Tregs), FoxP3expression in the infarct-related coronary artery, and peripheral veinousblood of patients with ST-segment elevation myocardial infarction.
Methods: We recorded 112 cases of patients with ST-segmentelevation myocardial infarction who were randomly assigned toreceive either atorvastatin 80 mg (n = 52) or placebo (n = 60) beforeprimary percutaneous coronary intervention. Blood samples wereobtained from the infarct-related coronary artery and peripheral veinduring percutaneous coronary intervention. The proportion ofCD4+CD25+ Tregs, FoxP3mRNA expression in blood and concentrationsof transforming growth factor-b and interferon-g inplasma of the samples were measured or detected by flow cytometry,real-time polymerase chain reaction, or enzyme-linked immunosorbentassay, respectively.
Results: In comparison with the control group, the proportions ofCD4+CD25+ Tregs and the mRNA level ofFoxP3andtransforminggrowthfactor-b significantly increased; however, interferon-gdecreased with atorvastatin therapy. In the controls, the proportions ofCD4+CD25+ Tregs and the mRNA level of FoxP3 and transforminggrowth factor-b were significantly decreased, but the level ofinterferon-g increased more intheinfarct-related coronary artery thanin the peripheral vein.
Conclusion: The inhibition of CD4+CD25+ Tregs in patients withST-segment elevation myocardial infarction could be regulatedwithatorvastatin given before percutaneous coronary intervention.
Key Words: STEMI, inflammation, statins, CD4+CD25+, Tregs,Foxp3
Methods: We recorded 112 cases of patients with ST-segmentelevation myocardial infarction who were randomly assigned toreceive either atorvastatin 80 mg (n = 52) or placebo (n = 60) beforeprimary percutaneous coronary intervention. Blood samples wereobtained from the infarct-related coronary artery and peripheral veinduring percutaneous coronary intervention. The proportion ofCD4+CD25+ Tregs, FoxP3mRNA expression in blood and concentrationsof transforming growth factor-b and interferon-g inplasma of the samples were measured or detected by flow cytometry,real-time polymerase chain reaction, or enzyme-linked immunosorbentassay, respectively.
Results: In comparison with the control group, the proportions ofCD4+CD25+ Tregs and the mRNA level ofFoxP3andtransforminggrowthfactor-b significantly increased; however, interferon-gdecreased with atorvastatin therapy. In the controls, the proportions ofCD4+CD25+ Tregs and the mRNA level of FoxP3 and transforminggrowth factor-b were significantly decreased, but the level ofinterferon-g increased more intheinfarct-related coronary artery thanin the peripheral vein.
Conclusion: The inhibition of CD4+CD25+ Tregs in patients withST-segment elevation myocardial infarction could be regulatedwithatorvastatin given before percutaneous coronary intervention.
Key Words: STEMI, inflammation, statins, CD4+CD25+, Tregs,Foxp3
